BioNTech (BNTX) to Release Earnings on Monday

BioNTech (NASDAQ:BNTX) is projected to issue its quarterly earnings data before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of $0.38 per share and revenue of $1.24 billion for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

BioNTech Stock Performance

Shares of BioNTech stock opened at $108.78 on Friday. BioNTech has a one year low of $76.53 and a one year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a market capitalization of $26.08 billion, a PE ratio of -51.80 and a beta of 0.30. The company has a 50-day simple moving average of $116.91 and a two-hundred day simple moving average of $112.76.

Wall Street Analysts Forecast Growth

BNTX has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $150.00 price objective on shares of BioNTech in a report on Monday, November 18th. BMO Capital Markets reiterated an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. Truist Financial started coverage on shares of BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 price target on the stock. Berenberg Bank started coverage on shares of BioNTech in a report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price target on the stock. Finally, Wells Fargo & Company started coverage on shares of BioNTech in a research note on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and an average price target of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.